Effect of rosiglitazone on blood glucose,pancreatic β cell function and inflammatory factors in early onset type 2 diabetes patients

Objective To investigate the effect of rosiglitazone on blood glucose,pancreatic β cell function and inflammatory factors in early onset type 2 diabetes patients.Methods All 50 cases of patients with type 2 diabetes were orally given the tablets of rosiglitazone 4 mg once daily,and the dosage will be increased to 8 mg once daily with a course of 12 weeks if the blood glucose dosen't reach satisfactory level after four weeks.Observe the blood glucose,the pancreatic β cell function and changes of plasma levels of inflammatory factors of the patients before and after therapy.Results After treated with rosiglitazone for 12 weeks,patients' fasting blood glucose(FBG),bedtime blood glucose,2 h postprandial blood glucose(2 hPG) and glycated hemoglobin(HbA1C) levels were significantly decreased(P 0.05 or P 0.01) compared with those before treatment,fasting C-peptide(FCP) and postprandial C-peptide(PCP) were significantly increased(P 0.05);plasma white of interleukin-6(IL-6),(hs-CRP) and tumor necrosis factor-α were significantly decreased(P 0.01 or P 0.05).Conclusion Rosiglitazone could not only lower blood glucose,but also improve pancreatic β-cell function and reduce inflammation,reduce the occurrence and development of diabetic vascular complications.